Bert W. O'Malley

In his research, he proposed that nuclear receptors function as transcription factors that regulate mRNA production in target cells in response to intracellular hormones. This hypothesis led him to uncover the detailed mechanisms activating steroid nuclear receptors (NRs) through the discovery of previously unidentified coactivators necessary for receptor-dependent gene transcription. In 1995, he successfully cloned the first coactivator, SRC-1, marking a significant advancement in the field. His identification of coactivators as critical elements in the regulation of the mammalian genome has significantly enhanced our molecular understanding of hormone action, including the effects of agonist and antagonist ligands and selective estrogen receptor modulators (SERMs). Over the course of more than 300 subsequent scholarly articles, his work underscored the crucial role of coactivators in a wide range of physiological processes and diseases, including genetics, reproduction, metabolism, inflammation, cardiovascular and central nervous system (CNS) functions, with a particular emphasis on cancer research. His laboratory's publication of the first structures of full-length estrogen receptor (ER)/SRC3/p300, androgen receptor (AR)/SRC2/p300, and progesterone receptor (PR)/SRC3/p300 complexes bound to DNA are considered landmark contributions to the field. Following these discoveries, he further explored the potential of coactivator- targeted approaches in medicine. ==Later career==

Bert O'Malley's early research greatly advanced the understanding of nuclear coactivator proteins and their role in the dysfunction of transcription processes associated with metabolic diseases, degeneration of the heart and brain, and notably, cancers. His work elucidated the structure and function of mammalian coregulator complexes, revealing their critical roles in transcription, oncogenic diseases, and tissue repair. This research paved the way for exploring coactivator-dependent therapies, with his laboratory discovering small molecule drugs aimed at regulating coactivators to address conditions such as cancer, metabolic diseases, stroke, and heart failure. Further investigations led O'Malley to identify a crucial function of the SRC-3 coactivator in immune T-regulatory cells, which play a protective role against autoimmunity but can also suppress the immune system's ability to kill cancer cells. His team developed a mouse model with the SRC-3 gene specifically deleted in T-regulatory cells, finding that this modification allowed T-conventional attack cells to effectively eliminate tumors. His lab's breakthrough demonstrated that these genetically modified animals exhibited a remarkable resistance to major cancers throughout their lifespan. O'Malley's group went on to pioneer a coactivator-centric adoptive cell transfer technique aimed at cancer treatment, showing that a single injection of SRC-3-deleted T-regulatory cells could permanently eliminate existing cancers without detectable toxicity. This method has been patented and will be developed by CoRegen-BCM for clinical application. Until his death, O'Malley led the Baylor Center for Coregulator Research, along with Drs. David Lonard, Sang-Jun Han, and Clifford Dacso. His contributions to the field of Endocrinology earned him recognition as the Father of Molecular Endocrinology. He was an elected member of the National Academies: of Sciences, of Medicine, and of Inventors. O'Malley received over 65 honors and major awards, including the National Medal of Science in 2008. Throughout his career, he mentored more than 220 scientists, published over 750 papers, and held 33 patents related to gene regulation, molecular endocrinology, steroid receptor-coactivator action, and molecular and cell-based medical therapies. ==Death==

O'Malley's death at the age of 88 was announced on November 11, 2025. ==Publications==

;Early career • • ;Middle career • • ;Later career • • ==References==